🧬 CAR-T Cell Therapy Guidelines – ICMR

Published by: Indian Council of Medical Research (ICMR), 2022
Relevance: GS Paper III (Science & Tech, Health), Prelims, Essay

---

🔬 What is CAR-T Cell Therapy?

Chimeric Antigen Receptor T-cell (CAR-T) therapy is an advanced type of immunotherapy where a patient's own T cells (a type of white blood cell) are genetically engineered to attack cancer cells.

---

🧪 How It Works – Simplified Steps

1. T Cell Collection → Blood is drawn from the patient.

2. Gene Modification → T cells are reprogrammed in a lab using viral vectors to express CARs (Chimeric Antigen Receptors).

3. Expansion → Modified T cells are multiplied.

4. Infusion → These CAR-T cells are infused back into the patient to seek and destroy cancer cells.

---

🧠 Why India Needs CAR-T Therapy Guidelines

• High demand for CAR-T in blood cancers (like B-cell leukemia and lymphoma).

• Until recently, all CAR-T therapies were imported, costing ₹3–4 crore.

• Indigenous research began under ICMR–DBT.

• The guidelines were issued in 2022 to support safe, ethical, and accessible development of CAR-T therapies in India.

---

🏛️ Key Provisions of ICMR Guidelines

1. 🧬 Product Classification

• CAR-T is classified as a Living Drug.

• Falls under the category of Advanced Therapy Medicinal Products (ATMPs).

2. 🧪 Clinical Trial Requirements

• Must follow ICMR’s National Guidelines for Stem Cell Research.

• Requires:

  • Pre-clinical data

  • Toxicity studies

  • Ethics Committee approval

  • Central Drugs Standard Control Organization (CDSCO) clearance

3. 🧑‍⚕️ Who Can Provide It?

• Only registered hospitals/institutes with:

  • GMP-certified cell processing labs

  • Expertise in oncology, hematology, and immunotherapy

4. 💉 Patient Safety

• Institutions must be ready to manage Cytokine Release Syndrome (CRS) – a common, dangerous side effect.

• Informed consent and long-term follow-up are mandatory.

5. 🔄 Gene Modification Guidelines

• Viral vectors (like lentivirus or retrovirus) must be rigorously tested to avoid insertional mutagenesis (unintended gene disruption).

• Non-viral methods are encouraged but still under development.

---

🇮🇳 India's Indigenous CAR-T Efforts

Institution	Product/Trial
IIT Bombay + Tata Memorial	A next-gen CAR-T trial named "H-CAR19"
ACTREC (Mumbai)	Early-stage leukemia therapy
ImmunoACT	Startup involved in commercial development

Cost Reduction Goal: Bring down CAR-T therapy cost from ₹4 crore to below ₹40 lakh.

---

🔐 Ethical & Regulatory Framework

• CAR-T involves genetic manipulation of human cells → hence regulated under:

  • Drugs & Cosmetics Act

  • National Guidelines for Gene Therapy Product Development (NGTPD)

  • Biomedical and Health Research Ethics Guidelines (ICMR)

---

🔍 Why It Matters for UPSC

🧾 GS Paper III:

• Health: Advances in cancer therapy

• Science & Tech: Biotechnology, genetic engineering, immunotherapy

• Ethics: Gene therapy, patient rights, safety concerns

📚 Prelims:

• ICMR, ACTREC, CAR-T, Living Drugs, ATMPs

✍️ Essay Ideas:

• “Innovation vs Accessibility: The Dilemma of High-End Therapies in India”

• “The Future of Cancer Treatment: Biology Rewrites Medicine”

---

📌 Sample MCQ

Q. Consider the following statements about CAR-T Cell Therapy in India:

1. It involves the use of genetically modified T cells to target cancer.

2. It has been approved by ICMR for treating all types of solid tumours.

3. Indigenous efforts are underway to reduce its cost and improve accessibility.

Which of the above is/are correct?

(a) 1 and 2 only

(b) 1 and 3 only

(c) 2 and 3 only

(d) All three

✅ Correct Answer: (b)

• Statement 2 is incorrect: CAR-T is currently used mostly for blood cancers, not solid tumours.

---

🚀 Way Forward for India

Challenge	Solution
High Cost	Subsidy schemes, indigenous R&D
Regulatory Delay	Single-window biotech clearance
Infrastructure Gaps	GMP labs in metro hospitals
Ethical Issues	Public awareness, consent protocols
Skilled Manpower	Training in gene editing, immunology

📌 Quick Facts

• First human CAR-T trial: 2010 (US)

• CAR-T Nobel Contribution: Based on T cell discovery, awarded in 2018 (James Allison and Tasuku Honjo)

• ICMR Guidelines Year: 2022

• CAR stands for: Chimeric Antigen Receptor